Investigators used machine learning approaches to integrate high-throughput transcriptomic, proteomic, metabolomic, and lipidomic profiles to provide novel critical molecular insights into Alzheimer’s Disease (AD) that single-omic analyses cannot offer.
Beth Israel Lahey Health has expanded its cardiovascular services to include heart transplantation based at Beth Israel Deaconess Medical Center.
Two studies are included: Total joint replacement outcomes in the unhoused and health literacy linked to shoulder arthroplasty outcomes
In this study, researchers at Beth Israel Deaconess Medical Center found that Black adults underwent significantly more endovascular peripheral vascular interventions (PVI), were treated for more advanced disease and were also more likely to experience adverse outcomes following PVI procedures, including amputation and death.
Researchers at Beth Israel Deaconess Medical Center conducted a comprehensive investigation of national trends in cardiovascular mortality among Black and white women and men across multiple socio-demographic domains and found a decline in cardiovascular mortality rates across all groups over the last 20 years.
Researchers report that exposure to cold temperatures resolved obesity-induced inflammation while improving insulin sensitivity and glucose tolerance in diet-induced obese mice.
In a new paper published in JAMA, researchers evaluated mental health and substance use among homeless and housed high school students surveyed voluntarily and anonymously in 2019.
Lahey Hospital & Medical Center (LHMC) today announced the opening of its new Hypertrophic Cardiomyopathy (HCM) medical and surgical center.
Scientists have demonstrated in mice that the benefits of exercise may also span generations.
Scientists sought to determine whether high blood glucose blunts the body’s response to exercise and whether lowering it can restore the ability to improve aerobic capacity with training.
Joslin Diabetes Center, the preeminent institution for diabetes research and care, affiliated with Harvard Medical School and a part of Beth Israel Lahey Health, has again been awarded $8.5 million from the National Institutes of Health/National Institute of Diabetes and Digestive and Kidney Diseases (NIH/NIDDK) in continued support for Joslin’s Diabetes Research Center (DRC) program. The grant, which officially began April 1, 2022, marks the 36th continuous year of NIH investment in Joslin’s DRC.
Reflecting on two years of the COVID-19 pandemic and its impact on society, we asked experts across Beth Israel Lahey Health about managing another year of the unknown, how to shore up our mental resources to heal from what we’ve been through and how to prepare for whatever may lie ahead.
Joslin Diabetes Center is pleased to announce that Chief Scientific Officer George L. King, MD, has been named the inaugural incumbent of the Thomas J. Beatson, Jr. Professorship in the Field of Diabetes at Harvard Medical School.
Beth Israel Lahey Health announced the opening of an on-site pharmacy at Bowdoin Street Health Center that will expand access to convenient medications for the health center’s approximately 11,000 patients other members of the Bowdoin-Geneva community in Massachusetts.
Beth Israel Lahey Health and Cape Cod Healthcare announced plans for a broad affiliation that will expand access to comprehensive care for patients, families and visitors on Cape Cod in Massachusetts.
Beth Israel Lahey Health (BILH) and Joslin Diabetes Center announced that Joslin has officially joined the BILH system.
A new analysis by a researcher at Beth Israel Deaconess Medical Center (BIDMC) finds a link between large gatherings of unvaccinated county residents – both students and non-students – and an increase in COVID-19 infections in the university’s community.
Physician-scientists from Beth Israel Deaconess Medical Center developed a 12-week mind-body program that takes a new approach to chronic back pain. The team demonstrated that the mind-body intervention was highly beneficial for treating back pain when compared to standard care
In a research letter in JAMA, physician-researchers at Beth Israel Deaconess Medical Center (BIDMC) found that the vast majority of patients who had a diagnosis of either cognitive impairment, Alzheimer’s disease, or Alzheimer’s disease related disorders, including cardiovascular disease, prior stroke, use of blood thinners, and age over 85 years, would have been excluded them from the aducanumab clinical trials.
A new analysis by a team of physician-researchers at Beth Israel Deaconess Medical Center (BIDMC) provides the first evidence that monoclonal antibodies were indeed underutilized in the first six months of FDA authorization.
RSS
Medicine keyboard_arrow_right
Sciencekeyboard_arrow_right
Life keyboard_arrow_right
Business keyboard_arrow_right
Journal News keyboard_arrow_right
By Location keyboard_arrow_right
Meetings, Grants, and Events keyboard_arrow_right